Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGF-1R antisense oligonucleotide
- Development stage
- Phase 1
- Lead developer
- Yuekang Pharmaceutical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intra-abdominal (in Cell Immunotherapy Context), Local Tumor Implantation (as Part Of Autologous Cell Therapy Product)
01
Overview
A synthetic antisense oligonucleotide designed to specifically bind to and inhibit translation of the mRNA of the human insulin-like growth factor 1 receptor (IGF-1R). By blocking IGF-1R expression, it disrupts the IGF signaling pathway that drives cell proliferation and survival in multiple tumors. Preclinical and clinical studies (e.g., CT102 and IGV-001) show effects including inhibition of tumor growth in hepatocellular carcinoma and potential immunostimulatory activity in glioblastoma, both as monotherapy and as part of combination immunotherapies[1][3][4][6][7].
- Brand names
- IGV-001IGV001IGV 001
- Other names
- IGF-1R ASOIGF1R ASOIGF 1R ASOIGF-1R antagonistsIGF1R antagonistsIGF 1R antagonists
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on IGF-1R antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGF-1R antisense oligonucleotide.